Precision medicine in nonalcoholic fatty liver disease: New therapeutic insights from genetics and systems biology

키워드

참고문헌 (59)

1. Brunt EM, "Nonalcoholic fatty liver disease", Nat Rev Dis Primers, 1, pp.15080~ (2015)
2. Pirola CJ, "Epigenetics factors in nonalcoholic fatty liver disease", Expert Rev Gastroenterol Hepatol (2020)[DOI]
3. Sookoian S, "Genetic predisposition in nonalcoholic fatty liver disease", Clin Mol Hepatol, 23, pp.1~12 (2017)
4. Sookoian S, "Genetics of nonalcoholic fatty liver disease : from pathogenesis to therapeutics", Semin Liver Dis, 39, pp.124~140 (2019)
5. Chalasani N, "Effects of belapectin, an inhibitor of galectin-3, in patients with nonalcoholic steatohepatitis with cirrhosis and portal hypertension", Gastroenterology, 158, pp.1334~1345.e5 (2020)
6. Garcia-Tsao G, "Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension", J Hepatol, 72, pp.885~895 (2020)
7. Harrison SA, "Simtuzumab is ineffective for patients with bridging fibrosis or compensated cirrhosis caused by nonalcoholic steatohepatitis", Gastroenterology, 155, pp.1140~1153 (2018)
8. Harrison SA, "Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH : results from randomized phase III STELLAR trials", J Hepatol, 73, pp.26~39 (2020)
9. Harrison SA, "A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis", J Hepatol, 72, pp.816~827 (2020)
10. Loomba R, "The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis : a randomized, phase 2 trial", Hepatology, 67, pp.549~559 (2018)
11. Ratziu V, "Why do so many NASH trials fail?", Gastroenterology (2020)[DOI]
12. Sookoian S, "Genetic pathways in nonalcoholic fatty liver disease : insights from systems biology", Hepatology, 72, pp.330~346 (2020)
13. Friedman SL, "Mechanisms of NAFLD development and therapeutic strategies", Nat Med, 24, pp.908~922 (2018)
14. Pirola CJ, "Multiomics biomarkers for the prediction of nonalcoholic fatty liver disease severity", World J Gastroenterol, 24, pp.1601~1615 (2018)
15. Sookoian S, "Intrahepatic bacterial metataxonomic signature in non-alcoholic fatty liver disease", Gut, 69, pp.1483~1491 (2020)
16. Sookoian S, "Repurposing drugs to target nonalcoholic steatohepatitis", World J Gastroenterol, 25, pp.1783~1796 (2019)
17. Romeo S, "Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease", Nat Genet, 40, pp.1461~1465 (2008)
18. Sookoian S, "A nonsynonymous gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity", J Lipid Res, 50, pp.2111~2116 (2009)
19. Sookoian S, "Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene(PNPLA3)on the susceptibility and histological severity of nonalcoholic fatty liver disease", Hepatology, 53, pp.1883~1894 (2011)
20. Abul-Husn NS, "A protein-truncating HSD17B13 variant and protection from chronic liver disease", N Engl J Med, 378, pp.1096~1106 (2018)
21. Kozlitina J, "Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease", Nat Genet, 46, pp.352~356 (2014)
22. Speliotes EK, "Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits", PLoS Genet, 7, pp.e1001324~ (2011)
23. Mancina RM, "The MBOAT7-TMC4 variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of european descent", Gastroenterology, 150, pp.1219~1230.e6 (2016)
24. Koo BK, "Additive effects of PNPLA3 and TM6SF2 on the histological severity of nonalcoholic fatty liver disease", J Gastroenterol Hepatol, 33, pp.1277~1285 (2018)
25. Lin YC, "Genetic determinants of hepatic steatosis and serum cytokeratin-18 fragment levels in Taiwanese children", Liver Int, 38, pp.1300~1307 (2018)
26. Sookoian S, "Lack of evidence supporting a role of TMC4-rs641738 missense variant-MBOAT7-intergenic downstream variant-in the susceptibility to nonalcoholic fatty liver disease", Sci Rep, 8, pp.5097~ (2018)
27. Anstee QM, "Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically-characterised cohort", J Hepatol, 73, pp.505~515 (2020)
28. Pirola CJ, "Splice variant rs72613567 prevents worst histologic outcomes in patients with nonalcoholic fatty liver disease", J Lipid Res, 60, pp.176~185 (2019)
29. Sookoian S, "Genetics meets therapy? Exomewide association study reveals a loss-of-function variant in 17-betahydroxysteroid dehydrogenase 13 that protects patients from liver damage and nonalcoholic fatty liver disease progression", Hepatology, 69, pp.907~910 (2019)
30. Sookoian S, "Liver tissue microbiota in nonalcoholic liver disease : a change in the paradigm of host-bacterial interactions", Hepatobiliary Surg Nutr (2020)[DOI]
31. Sookoian S, "Common genetic variations in CLOCK transcription factor are associated with nonalcoholic fatty liver disease", World J Gastroenterol, 13, pp.4242~4248 (2007)
32. Sookoian S, "Genetic variants of clock transcription factor are associated with individual susceptibility to obesity", Am J Clin Nutr, 87, pp.1606~1615 (2008)
33. Dongiovanni P, "Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease", Hepatology, 61, pp.506~514 (2015)
34. Sookoian S, "Nonalcoholic fatty liver disease and metabolic syndrome : shared genetic basis of pathogenesis", Hepatology, 64, pp.1417~1420 (2016)
35. Sookoian S, "Meta-analysis of the influence of TM6SF2E167K variant on plasma concentration of aminotransferases across different populations and diverse liver phenotypes", Sci Rep, 6, pp.27718~ (2016)
36. Zain SM, "Common variant in the glucokinase regulatory gene rs780094 and risk of nonalcoholic fatty liver disease : a meta-analysis", J Gastroenterol Hepatol, 30, pp.21~27 (2015)
37. Pirola CJ, "A rare nonsense mutation in the glucokinase regulator gene is associated with a rapidly progressive clinical form of nonalcoholic steatohepatitis", Hepatol Commun, 2, pp.1030~1036 (2018)
38. Kawaguchi T, "Risk estimation model for nonalcoholic fatty liver disease in the Japanese using multiple genetic markers", PLoS One, 13, pp.e0185490~ (2018)
39. Goh Eun Chung, "Genetic Polymorphisms of PNPLA3 and SAMM50 Are Associated with Nonalcoholic Fatty Liver Disease in a Korean Population", Gut and Liver, 12(3), pp.316~323 (2018), 거트앤리버 소화기연관학회협의회
40. Chande AT, "GlobAl Distribution of GEnetic Traits(GADGET)web server : polygenic trait scores worldwide", Nucleic Acids Res, 46, pp.W121~W126 (2018)
41. Mahdessian H, "TM6SF2 is a regulator of liver fat metabolism influencing triglyceride secretion and hepatic lipid droplet content", Proc Natl Acad Sci U S A, 111, pp.8913~8918 (2014)
42. Pirola CJ, "The dual and opposite role of the TM6SF2-rs58542926 variant in protecting against cardiovascular disease and conferring risk for nonalcoholic fatty liver : a meta-analysis", Hepatology, 62, pp.1742~1756 (2015)
43. Sookoian S, "Genetic variation in transmembrane 6 superfamily member 2 and the risk of nonalcoholic fatty liver disease and histological disease severity", Hepatology, 61, pp.515~525 (2015)
44. Farinelli E, "Valproic acid and nonalcoholic fatty liver disease : a possible association?", World J Hepatol, 7, pp.1251~1257 (2015)
45. Phiel CJ, "Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen", J Biol Chem, 276, pp.36734~36741 (2001)
46. Pirola CJ, "Epigenetic modification of liver mitochondrial DNA is associated with histological severity of nonalcoholic fatty liver disease", Gut, 62, pp.1356~1363 (2013)
47. Pirola CJ, "Epigenetic modifications in the biology of nonalcoholic fatty liver disease: the role of DNA hydroxymethylation and TET proteins", Medicine (Baltimore), 94, pp.e1480~ (2015)
48. Sookoian S, "Epigenetic regulation of insulin resistance in nonalcoholic fatty liver disease : impact of liver methylation of the peroxisome proliferator-activated receptor gamma coactivator 1alpha promoter", Hepatology, 52, pp.1992~2000 (2010)
49. Veitch K, "Inhibition of mitochondrial betaoxidation and peroxisomal stimulation in rodent livers by valproate", Biochem Soc Trans, 17, pp.1070~1071 (1989)
50. Sanyal AJ, "Nonalcoholic steatohepatitis : association of insulin resistance and mitochondrial abnormalities", Gastroenterology, 120, pp.1183~1192 (2001)
51. Sookoian S, "Mitochondrial genome architecture in non-alcoholic fatty liver disease", J Pathol, 240, pp.437~449 (2016)
52. Sookoian S, "Serum aminotransferases in nonalcoholic fatty liver disease are a signature of liver metabolic perturbations at the amino acid and Krebs cycle level", Am J Clin Nutr, 103, pp.422~434 (2016)
53. Lonardo A, "Sex differences in nonalcoholic fatty liver disease : state of the art and identification of research gaps", Hepatology, 70, pp.1457~1469 (2019)
54. Lonardo A, "Sexual Dimorphism of NAFLD in Adults. Focus on clinical aspects and implications for practice and translational research", J Clin Med, 9, pp.1278~ (2020)
55. Vandel J, "Hepatic molecular signatures highlight the sexual dimorphism of Non-Alcoholic SteatoHepatitis (NASH)", Hepatology (2020)[DOI]
56. Pirola CJ, "Liver mitochondrial DNA damage and genetic variability of Cytochrome b - a key component of the respirasome - drive the severity of fatty liver disease", J Intern Med. (2020)[DOI]
57. Rouillard AD, "The harmonizome: a collection of processed datasets gathered to serve and mine knowledge about genes and proteins", Database (Oxford), 2016, pp.baw100~ (2016)
58. Lachmann A, "Massive mining of publicly available RNA-seq data from human and mouse", Nat Commun, 9, pp.1366~ (2018)
59. Lachmann A, "ChEA : transcription factor regulation inferred from integrating genome-wide ChIP-X experiments", Bioinformatics, 26, pp.2438~2444 (2010)

관련 논문AI추천